➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
McKesson

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc. (D. Del. 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-08-13
Court District Court, D. Delaware Date Terminated 2017-05-16
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties BRECKENRIDGE PHARMACEUTICAL INC.; NOVARTIS AG; NOVARTIS PHARMACEUTICALS CORPORATION
Patents 6,004,973; 6,239,124; 6,440,990; 6,455,518; 8,410,131; 8,778,962
Attorneys Bruce J. Boggs; Christina Schwarz; Christopher E. Loh; Corinne E. Atton; Daniel M. Silver; Daniel R. Evans; Kelly E. Farnan; Laura K. Fishwick; Matthew L. Fedowitz; Michael P. Kelly; Nicholas N. Kallas; Selena E. Molina
Firms Richards, Layton & Finger, PA
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2016-09-26 162 POST Trial Brief of U.S. Patent No. 5,665,772 for Obviousness and the Invalidity of U.S. Patent Nos. 6,239,124 and 6,455,518…for Obviousness and for Obviousness-Type Double Patenting, by Breckenridge Pharmaceutical Inc.. (Farnan,… 2014 16 May 2017 1:14-cv-01043 830 Patent None District Court, D. Delaware External link to document
2016-10-17 169 POST Trial Brief Brief Regarding Noninfringement of U.S. Patent Nos. 6,239,124 and 6,455,518, by Breckenridge Pharmaceutical… 2014 16 May 2017 1:14-cv-01043 830 Patent None District Court, D. Delaware External link to document
2016-10-25 174 POST Trial Brief Obviousness of U.S. Patent No. 5,665,772, and Invalidity of U.S. Patent Nos. 6,239,124 and 6,455,518, by… 2014 16 May 2017 1:14-cv-01043 830 Patent None District Court, D. Delaware External link to document
2017-03-28 182 Opinion induced infringement of U.S. Patent No. 6,239,124 ("the '124 patent") and Roxane and Par … later patent that are not patentably distinct from claims in a commonly owned earlier patent."&…;772 PATENT A. Findings of Fact 1. The '990 patent is a proper double-patenting reference…finds the '990 patent is a proper double-patenting reference to the '772 patent, then the claims…post-DRAA patent to serve as a double patenting reference for a later expiring pre-DRAA patent would effectively External link to document
2017-04-03 184 Opinion induced infringement of U.S. Patent No. 6,239,124 ("the '124 patent") and Breckenridge, Roxane… later patent that are not patentably distinct from claims in a commonly owned earlier patent."&…;772 PATENT A. Findings of Fact 1. The '990 patent is a proper double-patenting reference…finds the '990 patent is a proper double-patenting reference to the '772 patent, then the claims…post-URAA patent to serve as a double patenting reference for a later expiring pre-URAA patent would effectively External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Harvard Business School
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.